Zhonghua Nei Ke Za Zhi. 2017 Jan 1;56(1):68-80. doi: 10.3760/cma.j.issn.0578-1426.2017.01.020.
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and has the largest disease burden in China. Aspirin is the most promising agent for the prevention of ASCVD in such a large population for its easy availability and relative effectiveness, although its use in primary prevention is still a subject of debate. The joint task force has reviewed the current evidence of aspirin use in healthy population and in patients with stable coronary artery disease, acute coronary syndrome, transient ischemic attack, stroke and peripheral artery disease. The consensus statement provides a practical algorithm for identifying those at a high 10-year ASCVD risk, with more than or equal to 10%, who may benefit from aspirin use. Recommendations for aspirin use in primary and secondary prevention of ASCVD in Chinese, as well as its safety and "resistance" issues, are also stated.
动脉粥样硬化性心血管疾病（ASCVD）是中国主要的死亡原因且疾病负担最重。阿司匹林因易于获取且相对有效，是在如此庞大人群中预防ASCVD最具前景的药物，尽管其在一级预防中的应用仍存在争议。联合工作组回顾了目前阿司匹林在健康人群以及稳定型冠状动脉疾病、急性冠状动脉综合征、短暂性脑缺血发作、中风和外周动脉疾病患者中应用的证据。该共识声明提供了一种实用的算法，用于识别那些10年ASCVD风险≥10%、可能从使用阿司匹林中获益的人群。还阐述了中国关于阿司匹林在ASCVD一级和二级预防中的使用建议及其安全性和“抵抗”问题。
